These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29768985)

  • 1. Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments.
    Gropp KE; Carlson CS; Evans MG; Bagi CM; Reagan WJ; Hurst SI; Shelton DL; Zorbas MA
    Toxicol Pathol; 2018 Jun; 46(4):408-420. PubMed ID: 29768985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment.
    Belanger P; Butler P; Butt M; Bhatt S; Foote S; Shelton D; Evans M; Arends R; Hurst S; Okerberg C; Cummings T; Potter D; Steidl-Nichols J; Zorbas M
    Toxicol Sci; 2017 Aug; 158(2):319-333. PubMed ID: 28525647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.
    LaBranche TP; Bendele AM; Omura BC; Gropp KE; Hurst SI; Bagi CM; Cummings TR; Grantham LE; Shelton DL; Zorbas MA
    Ann Rheum Dis; 2017 Jan; 76(1):295-302. PubMed ID: 27381034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphologic, stereologic, and morphometric evaluation of the nervous system in young cynomolgus monkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor.
    Butt M; Evans M; Bowman CJ; Cummings T; Oneda S; Shelton D; Zorbas M
    Toxicol Sci; 2014 Dec; 142(2):463-76. PubMed ID: 25326242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys.
    Zorbas M; Hurst S; Shelton D; Evans M; Finco D; Butt M
    Regul Toxicol Pharmacol; 2011 Mar; 59(2):334-42. PubMed ID: 21130822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developmental toxicity assessment of tanezumab, an anti-nerve growth factor monoclonal antibody, in cynomolgus monkeys (Macaca fascicularis).
    Bowman CJ; Evans M; Cummings T; Oneda S; Butt M; Hurst S; Gremminger JL; Shelton D; Kamperschroer C; Zorbas M
    Reprod Toxicol; 2015 Jun; 53():105-18. PubMed ID: 25461901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment.
    Brown MT; Herrmann DN; Goldstein M; Burr AM; Smith MD; West CR; Verburg KM; Dyck PJ
    J Neurol Sci; 2014 Oct; 345(1-2):139-47. PubMed ID: 25073573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period.
    Evans M; Butt M; Belanger P; Cummings T; Gremminger JL; Zorbas M
    Auton Neurosci; 2019 May; 218():51-53. PubMed ID: 30890348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.
    Hochberg MC
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S18-21. PubMed ID: 25527216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.
    Hochberg MC; Tive LA; Abramson SB; Vignon E; Verburg KM; West CR; Smith MD; Hungerford DS
    Arthritis Rheumatol; 2016 Feb; 68(2):382-91. PubMed ID: 26554876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.
    Shoji S; Suzuki A; Nouri P; Cai CH; Gaitonde P; Marshall S
    CPT Pharmacometrics Syst Pharmacol; 2023 Sep; 12(9):1358-1370. PubMed ID: 37470295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis.
    Leite VF; Buehler AM; El Abd O; Benyamin RM; Pimentel DC; Chen J; Hsing WT; Mazloomdoost D; Amadera JE
    Pain Physician; 2014; 17(1):E45-60. PubMed ID: 24452657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
    Bannwarth B; Kostine M
    Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factor.
    Liu S; Shen Y; Chen P; Guo C; Zhang G; Jiang X; He J; Yang J
    Protein Expr Purif; 2022 Jan; 189():105966. PubMed ID: 34627999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues.
    Bélanger P; West CR; Brown MT
    J Toxicol Sci; 2018; 43(1):1-10. PubMed ID: 29415946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
    Miller RE; Block JA; Malfait AM
    Curr Opin Rheumatol; 2017 Jan; 29(1):110-118. PubMed ID: 27672741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Toxicity and Neurological Effects of Fulranumab in Adult Cynomolgus Monkeys.
    Rocca M; Han C; Butt M; Coogan TP
    Int J Toxicol; 2019; 38(3):173-182. PubMed ID: 30852923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.
    Schnitzer TJ; Marks JA
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S8-17. PubMed ID: 25527221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain.
    Cattaneo A
    Curr Opin Mol Ther; 2010 Feb; 12(1):94-106. PubMed ID: 20140821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.